News
In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...
Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results